首页> 美国卫生研究院文献>AIDS Research and Human Retroviruses >Sensitivity Changes over the Course of Infection Increases the Likelihood of Resistance Against Fusion but Not CCR5 Receptor Blockers
【2h】

Sensitivity Changes over the Course of Infection Increases the Likelihood of Resistance Against Fusion but Not CCR5 Receptor Blockers

机译:感染过程中的敏感性变化增加了抗融合的可能性但没有增加CCR5受体阻滞剂的抵抗力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As HIV-1 evolves over the course of infection, resistance against antiretrovirals may arise in the absence of drug pressure, especially against receptor and fusion blockers because of the extensive changes observed in the envelope glycoprotein. Here we show that viruses from the chronic phase of disease are significantly less sensitive to CCR5 receptor and fusion blockers compared to early infection variants. Differences in susceptibility to CCR5 antagonists were observed in spite of no demonstrable CXCR4 receptor utilization. No significant sensitivity differences were observed to another entry blocker, soluble CD4, or to reverse transcriptase, protease, or integrase inhibitors. Chronic as compared to early phase variants demonstrated greater replication when passaged in the presence of subinhibitory concentrations of fusion but not CCR5 receptor inhibitors. Fusion antagonist resistance, however, emerged from only one chronic phase virus culture. Because sensitivity to receptor and fusion antagonists is correlated with receptor affinity and fusion capacity, respectively, changes that occur in the envelope glycoprotein over the course of infection confer greater ability to use the CCR5 receptor and increased fusion ability. Our in vitro passage studies suggest that these evolving phenotypes increase the likelihood of resistance against fusion but not CCR5 receptor blockers.
机译:随着HIV-1在感染过程中的发展,由于在包膜糖蛋白中观察到广泛的变化,在没有药物压力的情况下可能会产生对抗逆转录病毒药的耐药性,尤其是对受体和融合阻滞剂的耐药性。在这里,我们显示,与早期感染变体相比,来自疾病慢性病的病毒对CCR5受体和融合阻滞剂的敏感性明显较低。尽管没有可证明的CXCR4受体利用,但仍观察到对CCR5拮抗剂的敏感性差异。没有观察到对另一种进入阻断剂,可溶性CD4或逆转录酶,蛋白酶或整合酶抑制剂的显着敏感性差异。与早期变异相比,当在亚抑制浓度的融合而不是CCR5受体抑制剂存在的情况下传代时,慢性复制表现出更大的复制。然而,融合拮抗剂抗性仅从一种慢性病毒培养物中出现。因为对受体拮抗剂和融合拮抗剂的敏感性分别与受体亲和力和融合能力相关,所以在感染过程中包膜糖蛋白中发生的变化赋予了使用CCR5受体的更大能力和更高的融合能力。我们的体外传代研究表明,这些不断发展的表型增加了抗融合的可能性,但没有增加CCR5受体阻滞剂的抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号